JP2016502981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502981A5 JP2016502981A5 JP2015546778A JP2015546778A JP2016502981A5 JP 2016502981 A5 JP2016502981 A5 JP 2016502981A5 JP 2015546778 A JP2015546778 A JP 2015546778A JP 2015546778 A JP2015546778 A JP 2015546778A JP 2016502981 A5 JP2016502981 A5 JP 2016502981A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- solvate
- prodrug
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000002207 metabolite Substances 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 239000003172 expectorant agent Substances 0.000 claims description 9
- 229940066491 mucolytics Drugs 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 230000000975 bioactive effect Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 108010004032 Bromelains Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 235000019835 bromelain Nutrition 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 229940121672 Glycosylation inhibitor Drugs 0.000 claims description 3
- 230000004988 N-glycosylation Effects 0.000 claims description 3
- 102000003838 Sialyltransferases Human genes 0.000 claims description 3
- 108090000141 Sialyltransferases Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 206010073360 Appendix cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000011885 synergistic combination Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 241000222518 Agaricus Species 0.000 claims 2
- 241001327634 Agaricus blazei Species 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 108010063954 Mucins Proteins 0.000 description 13
- 102000015728 Mucins Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010059685 Sputum retention Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012905519A AU2012905519A0 (en) | 2012-12-17 | Treatment of diseases involving mucin | |
| AU2012905519 | 2012-12-17 | ||
| PCT/AU2013/001474 WO2014094041A1 (en) | 2012-12-17 | 2013-12-17 | Treatment of diseases involving mucin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502981A JP2016502981A (ja) | 2016-02-01 |
| JP2016502981A5 true JP2016502981A5 (OSRAM) | 2017-01-19 |
| JP6502853B2 JP6502853B2 (ja) | 2019-04-17 |
Family
ID=50977393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546778A Active JP6502853B2 (ja) | 2012-12-17 | 2013-12-17 | ムチンが関与する疾患の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11369666B2 (OSRAM) |
| EP (1) | EP2931296B1 (OSRAM) |
| JP (1) | JP6502853B2 (OSRAM) |
| KR (1) | KR102255753B1 (OSRAM) |
| CN (2) | CN104968358B (OSRAM) |
| AU (3) | AU2013362878B2 (OSRAM) |
| CA (1) | CA2895149C (OSRAM) |
| DK (1) | DK2931296T3 (OSRAM) |
| ES (1) | ES2727686T3 (OSRAM) |
| NZ (1) | NZ631536A (OSRAM) |
| TR (1) | TR201907858T4 (OSRAM) |
| WO (1) | WO2014094041A1 (OSRAM) |
| ZA (1) | ZA201503979B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521069A (ja) | 2015-07-16 | 2018-08-02 | プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 腹膜癌を治療するための組成物及び方法 |
| EP3362085B1 (en) * | 2015-10-14 | 2023-06-07 | Newsouth Innovations Pty Limited | Compositions for the treatment of diseases involving mucin |
| JPWO2017195792A1 (ja) * | 2016-05-13 | 2019-03-14 | 国立大学法人 熊本大学 | 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー |
| CN108066413A (zh) * | 2016-11-15 | 2018-05-25 | 李雁 | 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途 |
| AU2019225453B2 (en) * | 2018-02-23 | 2025-03-13 | MUCPharm Pty Ltd | Formulations containing mucin-affecting proteases |
| ES2988904T3 (es) | 2019-03-07 | 2024-11-22 | Nobo Medicine Inc | Inhibidores de caspasa y métodos de utilización de los mismos |
| WO2021217221A1 (en) * | 2020-05-01 | 2021-11-04 | MUCPharm Pty Ltd | Preventing and treating viral infections |
| JP2024539275A (ja) * | 2021-10-27 | 2024-10-28 | エムユーシーファーム ピーティーワイ リミテッド | 呼吸器疾患を治療するための方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE4302060A1 (de) * | 1993-01-26 | 1994-07-28 | Mucos Pharma Gmbh & Co | Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| CH695414A5 (de) * | 2001-05-30 | 2006-05-15 | Guenter Holzner | Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung. |
| US6517832B1 (en) * | 2001-08-24 | 2003-02-11 | Jeffrey L. Marrongelle | Formulations and methods for treating chronic migraine |
| AU2004294986B2 (en) * | 2003-11-26 | 2010-09-09 | Hill's Pet Nutrition, Inc. | Method to reduce stool odor of companion animals |
| CA2522152A1 (en) * | 2004-10-07 | 2006-04-07 | Kabushiki Kaisha Sangi | Transdermal and transmucosal preparations |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| US20080075710A1 (en) * | 2006-09-25 | 2008-03-27 | Liquid Potions Llc | Herbal composition for treating hangovers |
| US20100166726A1 (en) * | 2007-03-07 | 2010-07-01 | Northeastern University | Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation |
| TWI461193B (zh) * | 2009-07-24 | 2014-11-21 | Taipei Veterans General Hospital | 水飛薊或水飛薊賓用於治療神經受損之用途 |
| JP5614978B2 (ja) * | 2009-12-22 | 2014-10-29 | 独立行政法人農業・食品産業技術総合研究機構 | 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法 |
| CN103285383B (zh) * | 2013-06-03 | 2015-01-07 | 海南通用同盟药业有限公司 | 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片 |
-
2013
- 2013-12-17 CA CA2895149A patent/CA2895149C/en active Active
- 2013-12-17 JP JP2015546778A patent/JP6502853B2/ja active Active
- 2013-12-17 TR TR2019/07858T patent/TR201907858T4/tr unknown
- 2013-12-17 ES ES13866447T patent/ES2727686T3/es active Active
- 2013-12-17 AU AU2013362878A patent/AU2013362878B2/en active Active
- 2013-12-17 WO PCT/AU2013/001474 patent/WO2014094041A1/en not_active Ceased
- 2013-12-17 NZ NZ631536A patent/NZ631536A/en unknown
- 2013-12-17 EP EP13866447.9A patent/EP2931296B1/en active Active
- 2013-12-17 CN CN201380070938.4A patent/CN104968358B/zh active Active
- 2013-12-17 KR KR1020157018076A patent/KR102255753B1/ko active Active
- 2013-12-17 DK DK13866447.9T patent/DK2931296T3/da active
- 2013-12-17 US US14/649,518 patent/US11369666B2/en active Active
- 2013-12-17 CN CN202211366234.9A patent/CN116077631A/zh active Pending
-
2015
- 2015-06-03 ZA ZA2015/03979A patent/ZA201503979B/en unknown
-
2017
- 2017-06-29 AU AU2017204436A patent/AU2017204436B2/en active Active
-
2019
- 2019-05-12 AU AU2019203315A patent/AU2019203315A1/en not_active Abandoned
-
2022
- 2022-06-27 US US17/850,593 patent/US20220401529A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502981A5 (OSRAM) | ||
| JP2016006096A5 (OSRAM) | ||
| JP2013507415A5 (OSRAM) | ||
| JP2016515561A5 (OSRAM) | ||
| JP2017527532A5 (OSRAM) | ||
| JP2015212268A5 (OSRAM) | ||
| JP2012506870A5 (OSRAM) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2018168191A5 (OSRAM) | ||
| JP2017510610A5 (OSRAM) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2014525454A5 (OSRAM) | ||
| JP2016525097A5 (OSRAM) | ||
| JP2019507764A5 (OSRAM) | ||
| JP2012512164A5 (OSRAM) | ||
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| JP2015537009A5 (OSRAM) | ||
| JP2008514577A5 (OSRAM) | ||
| JP2012522841A5 (OSRAM) | ||
| JP2019506392A5 (OSRAM) | ||
| JP2014507412A5 (OSRAM) | ||
| JP2016514727A5 (OSRAM) | ||
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| JP2017516827A5 (OSRAM) | ||
| JP2015507020A5 (OSRAM) |